Ceribell, Inc. (CBLL)

In January 2026, Ceribell received FDA Breakthrough Device Designation for its LVO stroke detection and monitoring solution. In December 2025, the company announced FDA 510(k) clearance for its delirium monitoring solution. In November 2025, Ceribell received FDA 510(k) clearance for the use of its Clarity algorithm for neonates and reported its Third Quarter 2025 financial results, posting an EPS of -$0.37 and revenue of $22.59 million. In August 2025, Ceribell reported Second Quarter 2025 financial results, with total revenue increasing 38% to $21.2 million. Ceribell insiders have sold a notable amount of company stock, totaling $6,733,450.00 in the past three months. Between December 30, 2024, and December 26, 2025, the share price declined by 17.63%.

Information regarding the specific patterns of demand seasonality for Ceribell's products and services is limited. The pace of new account signings in Q2 2025 slowed compared to the prior quarter, which was attributed in part to "expected seasonal trends" and the maturation of the account base.

Ceribell, Inc. is a medical technology company focused on diagnosing and managing patients with neurological conditions. Its core offering is the Ceribell System, a point-of-care EEG platform for acute care settings. The Ceribell System is the primary platform for point-of-care EEG, enabling early detection and management of suspected seizure patients. Disposable Headbands consisting of ten non-invasive electrodes pre-filled with conductive gel are used with the Ceribell System. Pocket-sized Battery-operated Recorders record and store EEG signals generated by the headband. The Clarity AI Algorithm interprets EEG in real-time, providing bedside alerts and continuous monitoring. The Ceribell EEG Portal is a cloud-based secured portal that allows for real-time remote review of EEG data with pre-annotated insights.

Ceribell has a global presence through direct sales and distribution partnerships across North America, Europe, and select international markets. The company's solutions are utilized in hospitals, birthing centers, and audiology clinics.

Ceribell's brand reputation appears to be largely positive, driven by its innovative medical technology and regulatory achievements. The company has received a "Moderate Buy" consensus rating from eight analysts, with an average twelve-month price target of $24.67. News sentiment is "Very Bullish," and crowd wisdom is "Very Positive." The FDA Breakthrough Device Designation for LVO Stroke Detection highlights the potential of Ceribell's technology. Recent FDA 510(k) Clearances further establish the Ceribell System as an advanced AI-powered brain monitoring platform.

Ceribell, Inc. is primarily owned by institutional shareholders (69.80%), followed by Ceribell insiders (28.92%), and retail investors (1.28%). Major institutional owners include Fmr Llc, Tpg Gp A, Llc, Red Tree Management, LLC, BlackRock, Inc., Vanguard Group Inc, Yu Fan, ABG-WTT Global Life Science Capital Partners GP Ltd, TimesSquare Capital Management, LLC, Fidelity Small Cap Growth Fund (FCPGX), and Vanguard Total Stock Market Index Fund Investor Shares (VTSMX). Key individual insiders and significant shareholders include Tpg GP A LLC, Josef Parvizi, Bakker Juliet Tammenoms, and Xingjuan Chao (CEO).